MP36-06 EFFECTS OF GENDER-AFFIRMING HORMONE THERAPY ON SEXUAL FUNCTION OF TRANSGENDER MEN AND WOMEN

Abstract

Listen

Translate article

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (MP36)1 Sep 2021MP36-06 EFFECTS OF GENDER-AFFIRMING HORMONE THERAPY ON SEXUAL FUNCTION OF TRANSGENDER MEN AND WOMEN Michael Zaliznyak, Marie Lauzon, Jenna Stelmar, Nance Yuan, and Maurice Garcia Michael ZaliznyakMichael Zaliznyak More articles by this author , Marie LauzonMarie Lauzon More articles by this author , Jenna StelmarJenna Stelmar More articles by this author , Nance YuanNance Yuan More articles by this author , and Maurice GarciaMaurice Garcia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002045.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Transgender patients who present for medical and surgical care are treated with hormone medications and genital surgeries that affect, and often significantly change, sexual function. Although patients rely on providers to counsel them about what effects they might expect, the effects of such treatments on sexual function are not well described or understood. We sought to assess the impact of gender affirming hormone therapy (GAHT) on patients’ sexual function. METHODS: We queried potential changes in orgasm function before and after commencing GAHT (minimum 1 year) among 130 consecutive transgender women (TW) and 33 transgender men (TM). TW presented to either undergo initial vaginoplasty surgery (N=96), or who had previously had vaginoplasty (N=34), and all TM had no prior history of gender affirming genital surgery (n=33). We queried the following specific domains under a uniform condition (masturbation): 1. Lead-time to achieve orgasm, 2. Duration of orgasm, 3. Body location of orgasm sensation; 4. Description of orgasm as either a single or multiple-peak event, 5. Duration of post-orgasm refractory period, and 6. Overall satisfaction with orgasm quality. RESULTS: Within groups by gender, TW and TM cohorts reported similar responses to our inventory before starting GAHT. After GAHT, TW in both pre- and post-vaginoplasty surgery groups reported similar changes in orgasm function: increase in lead-time necessary to achieve orgasm, orgasm duration, and overall orgasm satisfaction; and decrease in post-orgasm refractory period. Similarly, TM reported an increase in duration of orgasm and overall satisfaction with orgasm quality; and a decrease in post-orgasm refractory period. Over half of the TW and TM patients reported experiencing orgasms in additional body locations. Additionally, prior to commencing GAHT, the majority of TM and TW patients reported their orgasms as a short, single-peak event but following GAHT these same patients reported longer and multiple-peak orgasms. Reported dissatisfaction was driven by longer time to orgasm. CONCLUSIONS: Our findings suggest that, with GAHT, TW and TM experience considerable change in several sexual function domains- but also improved overall orgasm quality and satisfaction. Interestingly, among TW, GAHT results in orgasm function and quality that more closely resembles what cis-women describe- something that has not been reported to date. It is important to share such data with patients prospectively before treatments. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e637-e638 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Zaliznyak More articles by this author Marie Lauzon More articles by this author Jenna Stelmar More articles by this author Nance Yuan More articles by this author Maurice Garcia More articles by this author Expand All Advertisement Loading ...